Sciometometric Mapping of Mucormycosis Research in Relation to the COVID-19 Pandemic

Devi Dayal1,*, Brij Mohan Gupta2, Mallikarjun Kappi3

ABSTRACT

Background: Mucormycosis is an invasive fungal infection that has shown a surge during the COVID-19 pandemic. A comprehensive assessment of COVID-19 associated mucormycosis (CAM) research is lacking. Methods: We searched Elsevier's Scopus database for publications on CAM using a pre-defined search strategy. Data on publications numbers, citation metrics, contributing countries, institutions, authors, journals, and the most cited articles were analyzed using select bibliometric tools. Results: Published CAM research included 253 publications. These were cited 1560 times, averaging 6.1 citations per paper. Only 33 (13%) were funded. Original articles (55.7%) and reviews (17.7%) constituted the major share of global output. The studied age groups included adults (22.5%), middle-aged (19.3%), elderly (10.6%), and adolescents (0.8%). Studies on treatment accounted for the largest share (58.5%), followed by clinical studies (28.0%), complications (17.3%), risk factors (11.7%), epidemiology (17.9%), and pathophysiology (3.1%). The participating countries were 64; India, the USA, and Egypt led in productivity, whereas France, the USA, and Iran were more impactful. Of the 84 organizations, the leading organizations were PGIMER-Chandigarh, AIIMS-New Delhi and Cairo University, Egypt. A. Chakrabarti, V. Muthu, and S.M. Rudramurthy were the most productive of 160 participating authors. Indian Journal of Ophthalmology, Indian Journal of Otolaryngology and Head and Neck Surgery, and Journal of Fungi were the most active journals that published CAM research. Conclusion: Research on CAM has primarily been conducted in middle-income countries and is low on quality. High-income countries need to collaborate with low- and middle-income countries for a sustainable and universal CAM research impact. There is also a need to focus on research gaps such as pathophysiology and epidemiology in future CAM research.

Key words: Coronavirus disease 2019, Fungal infections, COVID-19 associated mucormycosis, CAM, Bibliometrics.

INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in over five million deaths worldwide since its beginning in 2019.1 The mortality in those with comorbid conditions such as diabetes, obesity, or other prior chronic illnesses has been particularly massive.2,3 In addition, a host of life-saving interventions and prolonged hospitalizations also contribute to co-infections by various bacterial, viral, and fungal pathogens.4 The fungal co-infections in COVID-19 infected patients, in particular, produce devastating effects in affected patients with a several-fold increase in morbidity and mortality.5 Several fungi such as Aspergillus, Candida species, Cryptococcus neoformans, and the Mucorales have been reported to co-infect patients with COVID-19.6 The distribution of these co-infecting fungi, particularly Mucormycosis, has been found to be markedly skewed towards low- and middle-income countries, similar to their prevalence during the pre-COVID times.7-9 There are several challenges in the management of COVID-19 associated mucormycosis (CAM).10 Similar to patients with non-COVID-19 conditions, the mainstay of treatment of CAM involves extensive surgical debridement of the affected tissues and antifungals along with adequate control of the associated illness.11,12 An early diagnosis is also crucial for survival outcomes.12-14 However, the diagnosis of CAM is often delayed due to its non-specific initial symptoms and signs.10,12 Additionally, surgical debridement is often a challenge during pandemic times. In a recent report from India, surgery could be performed only in less than 50% of CAM-affected patients.15 Furthermore, a reversal of the predisposing immunosuppressed state often requires withdrawal of immunomodulatory drugs, which are the cornerstone for managing the cytokine storm in COVID-19 patients.10,12 To overcome these challenges, further research aimed at identifying risk factors for CAM, developing technologies for early and rapid diagnosis of CAM, and measures...
to minimize the dosage and duration of drugs such as corticosteroids, immunosuppressants, and antibiotics, has been suggested.\textsuperscript{7,10,11,12} Research is also needed to understand region-specific epidemiological and pathophysiological factors for a disproportionately increased incidence of CAM in certain countries.\textsuperscript{14} An assessment of the previously accomplished research is essential to guide future research in any field. Such an appraisal, usually achieved through scientometric or bibliometric analyses, helps the researchers to identify the research gaps and hotspots, thus allowing them to focus on areas that require more attention as compared to others.\textsuperscript{17} It also helps to identify researchers, organizations, funding agencies, and regions that share research interests which is necessary to foster collaborations leading to more impactful research.\textsuperscript{18-20} In connection with CAM, even though extensive research appears to have been conducted during the pandemic, scientometric assessment studies are scarce. Bibliometric studies on COVID-19 did not attempt to analyze research on CAM separately.\textsuperscript{21,22} Similarly, recent analyses of mucormycosis research included publications before the global surge in CAM infections.\textsuperscript{23-25} Two other bibliometric studies that focussed on CAM and included publications till May and August 2021, respectively, provided analyses of 154 and 51 publications only, far lower than would be expected of an evidently researched topic.\textsuperscript{26,27} Thus a comprehensive mapping of CAM research is still lacking. In the present contribution, we attempted to provide a bibliometric assessment of published research on CAM using the Scopus database.

OBJECTIVES

We aimed to evaluate published research on CAM as covered in the Scopus database since the onset of the COVID-19 pandemic until November 15, 2021. The study focused on the contribution of top countries, organizations, authors, journals, research collaborations, funding support, the impact of publications, and features of highly-cited papers (HCP).

MATERIALS AND METHODS

The relevant publications on CAM research were retrieved from the Scopus database (http://www.scopus.com) using a pre-defined search strategy similar to previous bibliometric studies.\textsuperscript{28-30} The following search string was used:

\texttt{TITLE ("covid 19" OR "2019 novel coronavirus" OR "coronavirus 2019" OR "coronavirus disease 2019" OR "2019-novel CoV" OR "2019 nov" OR covid 2019 OR corvidae OR "corona virus 2019" OR ncov-2019 OR ncov2019 OR "nov 2019" OR 2019-ncov OR covid-19 OR "Severe acute respiratory syndrome coronavirus 2" OR "SARS-CoV-2" ) OR KEY ( "covid 19" OR "2019 novel coronavirus" OR "coronavirus 2019" OR "coronavirus disease 2019" OR "2019-novel CoV" OR "2019 nov" OR covid 2019 OR corvidae OR "corona virus 2019" OR ncov-2019 OR ncov2019 OR "nov 2019" OR 2019-ncov OR covid-19 OR "Severe acute respiratory syndrome coronavirus 2" OR "SARS-CoV-2" ) and Key (mucormycosis*) OR Key (black fungus*)}

The data obtained were further examined using analytical provisions of the Scopus database. Using the complete counting method, each author or organization of multi-author publications was fully counted. To settle the issue of synonyms or homonyms in the names of authors, other specific fields such as affiliations were used. The qualitative assessment of publications was based on indices such as the Hirsch index (HI), citations per paper (CPP), and relative citation index (RCI). The CPP was obtained by mathematically dividing the number of citations by the number of publications. The RCI was derived by dividing the number of publication's citations by the average citations usually received by an article in the same field and then benchmarking that number against the median RCI for all NIH-funded papers. The HI was calculated by counting the number of publications for which an author has been cited the same number of times. A publication was considered HCP if it had received more than 30 citations. The citations were counted from the date of publication until November 15, 2021.

Ethical considerations

The present study used secondary data for which approval from the ethics committees is not required. We, nevertheless, followed all the ethical principles recommended for analysis of this nature through respecting ideas, and citations, and referencing authors and publications.

RESULTS

General description of CAM publications

A majority (239, 94.4%) of the total 253 publications on CAM research were reported in the year 2021. The total citations and average CPP were 1560 and 6.1, respectively. Only 33 (13.0%) were externally funded; these received 155 citations, averaging 4.7 CPP. The major funding agencies were the National Institute of Health, USA (4 papers), Gilead Sciences and Pfizer (3 papers each), Department of Science and Technology, India, Hyderabad Eye Research Foundation, and Science and Engineering Board India (2 papers each). The publication categories were original articles (55.7%), reviews (17.8%), letters (13.8%), editorials (5.5%), notes (4.3%), short surveys (1.5%) and conference papers (1.2%). The distribution of publications by the studied age groups was as follows: adults (22.5%), middle-aged (19.3%), elderly (10.6%), and adolescents (0.8%). The most researched aspects of CAM were treatment (51.7%), followed by clinical studies (28.0%), complications (17.4%), and risk factors (11.8%). Epidemiology (7.9%), and pathophysiology (3.1%), were the least studied aspects of CAM. Research on complications and treatment registered the highest and lowest citation impact with average CPP of 16.8 and 7.7, respectively. According to the type of CAM, rhino-orbital-cerebral, cutaneous, pulmonary, and renal forms constituted 12.6%, 5.2%, 5.1%, and 4.7%, respectively. Diabetes mellitus was the most commonly studied risk factor (32.4% publications), followed by corticosteroid therapy (12.2%), diabetic ketoacidosis and immunocompromised host (3.5% each), chronic kidney disease (3.1%), neutropenia (2.3%), and hemodialysis (1.6%). To elucidate focus and trends in CAM research, we identified several significant keywords, as shown in Figure 1.

Figure 1: Network author keywords in COVID-associated mucormycosis (CAM) research. Each colour represents repetition of keywords occurring at least 5 times. The size of the node and the thickness of connecting lines represent their importance in CAM research.
Most productive countries
Sixty-four countries participated unevenly in global CAM research; 57 contributed 1-5 papers each, four countries 6-10 papers each, two countries 11-30 papers, and one country 153 papers. The top 10 countries together contributed 241 (95.2%) publications and 1542 (98.9%) citations. Table 1 shows the productivity and impact of countries. France, the USA, and Iran produced more impactful research registering their CPP and RCI above the group average of 6.4 and 1.0, respectively. The average international collaborative papers (ICP) was 33.6%. All the top 10 countries showed one-to-one collaboration; India, the USA, and Saudi Arabia established the largest number of linkages (25, 14, and 8, respectively). The country pairs that collaborated the highest number of times were India-USA (6 linkages), and India-Bangladesh, India-Pakistan, and India-Australia (4 linkages each).

The output of research organizations
Eighty-four organizations participated in CAM. Five organizations registered their publication output above the group average of 4.7, whereas five others recorded their CPP and RCI above the group average of 6.3 and 1.0, respectively (Table 2). The highest number of collaborations were shown by PGIMER-Chandigarh, AIIMS-New Delhi, and Saveetha Dental College and Hospital (5, 4, and 4 respectively). The organizations that paired maximally for collaboration were Saveetha Dental College and Hospital and Saveetha Institute of Medical and Technical Sciences (4 times), followed by MAMC-Delhi and Lok Nayak Hospital, New Delhi (3 times), and BJ Medical College, Ahmedabad and...
Table 3: Most productive and most impactful authors in COVID-associated mucormycosis research.

| S.no. | Name               | Affiliation                                      | TP | TC   | CPP  | HI  | ICP   | %ICP | RCI |
|-------|--------------------|--------------------------------------------------|----|------|------|-----|-------|------|-----|
| Most prolific authors |
| 1     | A. Chakrabarti     | PGIMER-Chandigarh                                | 6  | 116  | 19.3 | 3   | 2     | 33.3 | 3.1 |
| 2     | V. Muthu           | PGIMER-Chandigarh                                | 5  | 112  | 22.4 | 3   | 1     | 20.0 | 3.6 |
| 3     | S.M. Rudramurthy   | PGIMER-Chandigarh                                | 5  | 42   | 8.4  | 2   | 2     | 40.0 | 1.3 |
| 4     | R. Agarwal         | PGIMER-Chandigarh                                | 4  | 98   | 24.5 | 2   | 0     | 0.0  | 3.9 |
| 5     | K. Dhama           | IVRI-Bareilly                                    | 3  | 5    | 1.6  | 2   | 3     | 100.0| 0.2 |
| 6     | R. Goel            | MAMC-Delhi                                       | 3  | 0    | 0.0  | 0   | 0     | 0.0  | 0.0 |
| 7     | T. Gokhale         | JIPMER-Pondicherry                               | 3  | 64   | 21.3 | 2   | 0     | 0.0  | 3.4 |
| 8     | M.M. Hasan         | Mawlana Bhashani S&T University, Bangladesh      | 3  | 17   | 5.6  | 2   | 3     | 100.0| 0.9 |
| 9     | S.G. Honacar       | Center for Sight, Hyderabad                      | 3  | 123  | 41.0 | 3   | 0     | 0.0  | 6.6 |
| 10    | J. Kumat           | MAMC-Delhi                                       | 3  | 0    | 0.0  | 0   | 0     | 0.0  | 0.0 |
| Most impactful authors |
| 1     | S.G. Honacar       | Center for Sight, Hyderabad                      | 3  | 123  | 41.0 | 3   | 0     | 0.0  | 6.6 |
| 2     | M. Sen             | Center for Sight, Hyderabad                      | 3  | 121  | 40.3 | 3   | 0     | 0.0  | 6.5 |
| 3     | I.S. Sehgal        | PGIMER-Chandigarh                                | 3  | 96   | 32.0 | 2   | 0     | 0.0  | 5.1 |
| 4     | A. Misra           | Fortis-Doc, Gurgaon                             | 3  | 92   | 30.6 | 3   | 0     | 0.0  | 4.9 |
| 5     | R. Agarwal         | PGIMER-Chandigarh                                | 4  | 98   | 24.5 | 2   | 0     | 0.0  | 3.9 |
| 6     | V. Muthu           | PGIMER-Chandigarh                                | 5  | 112  | 22.4 | 3   | 1     | 20.0 | 3.6 |
| 7     | T. Gokhale         | JIPMER-Pondicherry                               | 3  | 64   | 21.3 | 2   | 0     | 0.0  | 3.4 |
| 8     | A. Chakrabarti     | PGIMER-Chandigarh                                | 6  | 116  | 19.3 | 3   | 2     | 33.3 | 3.1 |
| 9     | A. Sunavala        | PD Hinduja National Hospital and Medical Research Center, Mumbai | 3  | 26   | 8.6  | 1   | 0     | 0.0  | 1.4 |
| 10    | S.M. Rudramurthy   | PGIMER-Chandigarh                                | 5  | 42   | 8.4  | 2   | 2     | 40.0 | 1.3 |

Abbreviations: TP=total publications; TC=total citations; CPP=citations per paper; ICP=international collaborative papers; HI=Hirsch index; RCI=relative citation index.

Civil Hospital, Ahmedabad (3 times), and PGIMER-Chandigarh and AIIMS-New Delhi (2 times).

Leading authors
Of the 160 authors who participated in CAM research, the top four in productivity were A. Chakrabarti (6 papers), V. Muthu and S. Rudramurthy (5 papers each), and R. Agarwal (4 papers). Table 3 shows the profile of the most prolific and influential authors. All the leading authors showed collaborations; V. Muthu, A. Chakrabarti, and R. Agarwal had the largest linkages, i.e., 14, 13, and 11. Figure 2 shows the networking between authors for CAM research.

Top journals
All 253 papers on CAM research were published in 140 journals. Only two journals published 15–18 papers, three published 6–10, and the rest 135 published 1–5 papers each. The top 15 most productive journals accounted for a 37.1% share of global output (Table 4).

Impactful publications
Seventeen (6.72%) publications had received 30 to 91 citations each and were assumed to be HCPs. Their total and average citations were 931 and 54.7, respectively. India and the USA contributed eight and six publications, respectively, while Brazil, China, France, Greece, Iran, and Nigeria contributed one HCP each. Eleven HCPs were published as original articles, three as reviews, two as editorials, and one as a letter. Nine HCPs involved collaborative research; eight of these were national and one international collaborative. Eight HCPs were non-collaborative. The 17 HCPs were published in 14 journals; the Indian Journal of Ophthalmology was the leading journal that published three HCPs, whereas Journal de Mycologie Medicale published the most cited (91 times) article on CAM.

DISCUSSION
Our analysis revealed that the COVID-19 related mucormycosis research was mainly carried out in the low- and middle-income countries, unlike research in several other medical fields during COVID-19 pandemic or even during pre-COVID-19 times, which shows domination by high-income countries of North America or Western Europe.21-24,30-32 This is understandable as the low- or middle-income countries were particularly hit by the dual burden of COVID-19 and CAM.6,7 But even while the productivity of organizations and authors from low- and middle-income countries was substantial, it was the high-income countries such as France and the USA that led in CAM research impact. The high quality of research from high-income countries may be attributed to the availability of infrastructure and financial support and commitment to research by the national governments.33 In contrast, the paucity of funding and infrastructure in low-income countries affects the research quality.34 It is
thus imperative that high-income countries support research endeavors and collaborations with low- and middle-income countries to produce a more meaningful universal research in CAM, similar to research capacity strengthening initiatives for other diseases.\textsuperscript{35}

A notable finding of our study was the meager quantity of research and collaborations with low- and middle-income countries to produce a more meaningful universal research in CAM, similar to research capacity strengthening initiatives for other diseases.\textsuperscript{35}

A notable finding of our study was the meager quantity of research and collaborations with low- and middle-income countries to produce a more meaningful universal research in CAM, similar to research capacity strengthening initiatives for other diseases.\textsuperscript{35}

A notable finding of our study was the meager quantity of research and collaborations with low- and middle-income countries to produce a more meaningful universal research in CAM, similar to research capacity strengthening initiatives for other diseases.\textsuperscript{35}

A notable finding of our study was the meager quantity of research and collaborations with low- and middle-income countries to produce a more meaningful universal research in CAM, similar to research capacity strengthening initiatives for other diseases.\textsuperscript{35}

A notable finding of our study was the meager quantity of research and collaborations with low- and middle-income countries to produce a more meaningful universal research in CAM, similar to research capacity strengthening initiatives for other diseases.\textsuperscript{35}

A notable finding of our study was the meager quantity of research and collaborations with low- and middle-income countries to produce a more meaningful universal research in CAM, similar to research capacity strengthening initiatives for other diseases.\textsuperscript{35}

A notable finding of our study was the meager quantity of research and collaborations with low- and middle-income countries to produce a more meaningful universal research in CAM, similar to research capacity strengthening initiatives for other diseases.\textsuperscript{35}

CONCLUSION

Research on mucormycosis in relation to the COVID-19 pandemic has largely been conducted in middle-income countries and lacks quality. There is a need for high-income countries to collaborate with low- and middle-income countries for a sustainable and universal CAM research impact. Pathophysiology and epidemiology also need attention in future CAM research.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1. Worldometer. COVID-19 coronavirus death toll; updated Dec 25, 2021. Available from: https://www.worldometers.info/coronavirus/coronavirus-death-toll [cited 27/1/2022].
2. Alhasan KA, Shalaby MA, Temsah MH, Aljamaan F, Shagal R, AlFaadhel T, et al. Factors that influence mortality in critically ill patients with SARS-CoV-2 infection: A multicenter study in the Kingdom of Saudi Arabia. Healthcare (Basel). 2021;9(12):16088. doi: 10.3390/healthcare9121608, PMID 34944347.
3. Gupta BM, Pai R, Rohilla L, Dayal D. Bibliometric analysis of diabetes research in relation to the COVID-19 pandemic. J Diabetol. 2021;12(3):350-6. doi: 10.4103/ JOD.JOD_30_21.
4. Eskenazi B, Rauch S, Iurilo E, Gunier RB, Gravett MG, et al. Diabetes mellitus, maternal adiposity, and insulin-dependent gestational diabetes are associated with Covid-19 in pregnancy: The INTERCOVID Study. Am J Obstet Gynecol. 2021 Dec 20;203(8):S0002. doi: 10.1016/j.ajog.2021.12.032 [Epub ahead of print]. PMID 34942154.
5. Paparoupa M, Aldemiyati R, Roggenkamp H, Berinson B, Nörz D, Olearo F, et al. The prevalence of early-and late-onset bacterial, viral, and fungal respiratory superinfections in invasively ventilated COVID-19 patients. J Med Virol. 2021 Dec 24. doi: 10.1002/jmv.27548 [Epub ahead of print]. PMID 34951498.
6. Hussain S, Riad A, Singh A, Klugaro J, Antony B, Banna H, et al. Global prevalence of COVID-19-Associated mucormycosis (CAM): living systematic review and meta-analysis. J Fungi (Basel). 2021;7(11):985. doi: 10.3390/jfd7110985, PMID 34629271.
7. Amin A, Vartanian N, Voloshko A, Yegiazaryan A, Al-Kassir AL, et al. Root causes of fungal Coinfections in COVID-19 infected patients. Infect Dis Rep. 2021;13(4):1018-35. doi: 10.3390/idr13040093, PMID 34940403.
8. Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel). 2019;5(1):26. doi: 10.3390/jof5010026, PMID 30981907.
9. Dayal D, Jain P, Kumar R, Baskhi J, Menon P, Das A, et al. Clinical spectrum and outcome of invasive filamentous fungal infections in children with Type 1 diabetes: North Indian experience. Clin Pediatr Endocrinol. 2015;24(2):51-7. doi: 10.1299/cpe.24.51, PMID 26019401.
10. Yassin F, Najeib H, Naeem A, Dapke K, Phadke R, Asghar MS, et al. COVID-19-associated mucormycosis: A systematic review from diagnostic challenges to management. Diseases. 2021;9(4):65. doi: 10.3390/diseases9040065, PMID 34898143.
11. Dayal D. A multimodal approach is necessary to manage mucormycosis in patients with diabetes. J Clin Diagn Res. 2016;10(9):SLO1. doi: 10.7860/JCDR/2016/21349.8477, PMID 27790641.
12. Rudrabhatla PK, Reghukumar A, Thomas SV. Mucormycosis in COVID-19 patients: predisposing factors, prevention and management. Acta Neurol Belg. 2021 Nov 24:1-8. doi: 10.1007/s13760-021-01840-w [Epub ahead of print]. PMID 34620767.
13. Dayal D, Baskhi J. Early diagnosis and surgery is crucial to survival outcome in rhinocerebral mucormycosis. Indian J Otolaryngol Head Neck Surg. 2016;68(2):261-2. doi: 10.1007/s12098-016-1680-4, PMID 25589195.
14. Dayal D, Baskhi J, Jain P, Shivaparakash MR, Singh S. Outcome of rhino-sinus mucormycosis in children with Type 1 diabetes. Indian J Pediatr. 2015;82(7):651-2. doi: 10.1007/s12098-014-1680-4, PMID 25589195.
15. Choksi T, Agrawal A, Date P, Rathod D, Ghurat A, Ingole A, et al. Cumulative mortality and factors associated with outcomes of mucormycosis after COVID-19 at a multispecialty tertiary care center in India. JAMA Ophthalmol. 2022;140(1):66-72. doi: 10.1001/jamaophthalmol.2021.5201 [Epub ahead of print]. PMID 34820192.
16. Muthu V, Rudramurthy SM, Chakrabarti A, Agrawal R. Epidemiology and pathophysiology of COVID-19-Associated mucormycosis: India versus the rest of the world. Mycopathologia. 2021;186(8):739-54. doi: 10.1007/s11046-021-00694-8, PMID 34414555.
17. Cooper JD. Bibliometrics basics. J Med Libr Assoc. 2015;103(4):217-8. doi:
Dayal, et al.: COVID-associated Mucormycosis Research

10.3163/1536-5050.103.4.013, PMID 26512226.

18. Gupta BM, Dayal D. Pediatric type 1 diabetes research in the 21st century: A scientometric review. Pediatr Endocrinol Diabetes Metab. 2020;28(3):132-9. doi: 10.5114/pedm.2020.98165, PMID 32901470.

19. Dayal D, Gupta BM, Gupta S. Quantitative and qualitative assessment of Indian research yield in type 1 diabetes during 1996-2019. J Diabetol. 2021;12(1):29-35.

20. Gupta BM, Sikka P, Gupta S, Dayal D. Indian research in gestational diabetes mellitus during the past three decades: A Scientometric analysis. J Obstet Gynaecol India. 2021;71(3):254-61. doi: 10.1007/s13224-021-01444-7, PMID 34408344.

21. Gupta BM, Dhawan SM, Mueen Ahmed KK, Mamdapur GM. Global research on COVID-19 disease: A scientific assessment of publications during 2020-21. IJMEDPH. 2021;11(2):76-84. doi: 10.5530/ijmedph.2021.2.14.

22. Gupta BM. India's research on Covid-19: A Scientometric assessment of Publications 2019-21. J Young Pharm. 2021;13(3s):s30-41. doi: 10.5530/jyp.2021.13s.68.

23. Gupta BM, Mamdapur GM, Dayal D. Black Fungus (Mucormycosis) Research in India during 1998-2021: A Scopus-based Scientometric Analysis. IJMEDPH. 2021;11(3):133-8. doi: 10.5530/ijmedph.2021.3.24.

24. Gupta BM, Mamdapur GM, Gupta S, Rohilla L, Dayal D. Global mucormycosis research: A bibliometric assessment based on Scopus database (1998-2021). J Young Pharm. 2021;13(4):356-62. doi: 10.5530/jyp.2021.13.89.

25. Sivankalai S, Sivasekaran K. Mucormycosis (Black Fungus) Maiming Covid Patients: Scientometrics analysis through prism of Biblioshiny. Libr Philos Pract. 2021;5546.

26. Mallikarjun K. Bibliometric Visualisation of Research Performance of Post COVID-19 and Mucormycosis: Where Do We Stand? J Drug Delivery Ther;11(6):31-9. doi: 10.4103/jddt.jddt_5127.

27. Sharma P, Dubey G. Publications on post-Covid mucormycosis: A bibliometric study of WHO database. Bangladesh J Med Sci. 2021;20(5):144-7 doi: 10.3329/bjms.v20i5.55415.

28. Dayal D, Gupta BM, Bansal M, Nanda PM. Covid-19 and thyroid: A Scopus-based bibliometric assessment of research output. J Young Pharm. 2021;13(3a):s84-8. doi: 10.5530/jyp.2021.13s.76.

29. Dayal D, Gupta BM, Suruliniath M, Nanda PM. Covid-19 and Vitamin D deficiency: A Scientometric assessment of global publications during 2020-21. J Young Pharm. 2021;13(3a):s89-94. doi: 10.5530/jyp.2021.13s.77.

30. Dayal D, Gupta BM, Suruliniath M, Nanda PM. Covid-19 and Type 1 Diabetes: A Scientometric Assessment of Global Publications based on the Scopus Database. J Young Pharm. 2021;13(3a):s95-s100. doi: 10.5530/jyp.2021.13s.78.

31. Dayal D, Gupta BM, Gupta A. Thyroid disorders in children and adolescents: Systematic mapping of global research over the past three decades. Thyroid Res Pract. 2021;18(1):23-30. doi: 10.4103/trp.trp.5_21.

32. Dayal D, Gupta BM, Mamdapur GM, Rohilla L, Nanda PM. Stem cell therapy for type 1 diabetes: A scientometric assessment of global research during the 21st century. J Diabetes Metab Disord. 2022 (in press).

33. Moses H 3rd, Matheson DH, Cairns-Smith S, George BP, Polsich S, Dorsey ER. The anatomy of medical research: US and international comparisons. JAMA. 2015;313(2):174-89. doi: 10.1001/jama.2014.15939, PMID 25585329.

34. Lakhokia SC. Research fund crunch, real or created, is hitting India’s Academia on the Wrong Side. Proc Indian Natl Sci Acad. 2018;86(3):545-7. doi: 10.16943/ptinsa/2018/49475.

35. Haregu TN, Byrnes A, Singh K, Sathish T, Pasricha N, Wickramasinghe K, et al. A scoping review of non-communicable disease research capacity strengthening initiatives in low and middle-income countries. Glob Health Res Policy. 2019;4:31. doi: 10.1186/s41256-019-0123-1, PMID 31799408.

36. Rastogi A, Jude EB. Diabetes, COVID-19 and mucormycosis: Unanswered questions! Indian J Endocrinol Metab. 2021;25(3):191-2. doi: 10.4103/ijem.ijem_284_21, PMID 34760671.

37. Al-Tawfiq JA, Alhumaid S, Alshukairi AN, Temsah MH, Barry M, Al Mutair A, et al. COVID-19 and mucormycosis superinfection: the perfect storm. Infection. 2021;49(5):833-53. doi: 10.1007/s15010-021-01670-1, PMID 34302291.

38. Heyard R, Hottenrott H. The value of research funding for knowledge creation and dissemination: A study of SNSF Research Grants. Humanit Soc Sci Commun. 2021;8(1):217. doi: 10.1057/s41599-021-00891-x.

39. Kokol P, Volner HB. Discrepancies among Scopus, Web of Science, and PubMed coverage of funding information in medical journal articles. J Med Libr Assoc. 2018;106(1):81-6. doi: 10.1195/jmla.2018.181, PMID 29339937.

40. Baas J, Schotten M, Plume A, Côté G, Karimir R. Scopus as a curated, high-quality bibliometric data source for academic research in quantitative science studies. Quant Sci Stud. 2020;11(1):377-86. doi: 10.1162/qss_a_00019.